{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:45:46Z","timestamp":1789865146824,"version":"4.0.1"},"reference-count":24,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Background: Late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) is a rare neurodegenerative disease that generally appears in children between 2 and 4 years old, leading to seizures and a progressive loss of language and motor functions. As the disease progresses, affected individuals typically experience blindness and ultimately pass away in late childhood. Treatment with intracerebroventricular cerliponase alfa has been shown to slow the deterioration of motor and language functions compared to the natural progression of the disease. We aim to highlight the early symptoms of CLN2 which help with early diagnosis and timely treatment initiation in children with specific medical indications, as well as identify medical contraindications for enzyme replacement therapy. Methods: We describe five Croatian patients and one Bosnia and Herzegovinian patient with CLN2 disease, analyzing the clinical characteristics, neuroimaging findings, electroencephalogram results, genetic analysis, treatment indications and contraindications, and disease progression. Results: All six patients presented with seizures: focal seizures (n = 1), myoclonic\u2013atonic seizures (n = 1), febrile seizures (n = 2), and tonic\u2013clonic seizures (n = 2), along with language delay (n = 6). Despite this, one patient refused treatment, two were initially included in the clinical trial and then continued treatment, one did not indicate starting treatment, and three continued treatment. One patient, after 4.5 years of treatment, no longer had medical indications for the therapy, which was discontinued. The other two patients who received treatment had a significant slowing of disease progression. Conclusions: The early onset of seizures between ages 2 and 4, alongside delayed language development, is a defining characteristic of CLN2 disease. Enzyme replacement therapy using cerliponase alfa represents the initial treatment for neuronal ceroid lipofuscinosis type 2, targeting the underlying cause of the disease. It effectively delays the progression of language and motor decline in patients diagnosed with this condition.<\/jats:p>","DOI":"10.3390\/jpm14080783","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T14:55:47Z","timestamp":1721832947000},"page":"783","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Early Symptoms and Treatment Outcomes in Neuronal Ceroid Lipofuscinosis Type 2: Croatian Experience"],"prefix":"10.3390","volume":"14","author":[{"given":"Jelena","family":"Radi\u0107 Ni\u0161evi\u0107","sequence":"first","affiliation":[{"name":"Division of Child Neurology, Department of Pediatrics, Clinical Hospital Center, 51000 Rijeka, Croatia"},{"name":"Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Koli\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Kostanjski","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franka","family":"Kova\u010devi\u0107","sequence":"additional","affiliation":[{"name":"Division of Child Neurology, Department of Pediatrics, Clinical Hospital Center, 51000 Rijeka, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Prpi\u0107","sequence":"additional","affiliation":[{"name":"Division of Child Neurology, Department of Pediatrics, Clinical Hospital Center, 51000 Rijeka, Croatia"},{"name":"Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.bbadis.2013.04.008","article-title":"NCL diseases\u2014Clinical perspectives","volume":"1832","author":"Schulz","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Mole, S.E., Williams, R.E., Goebel, H.H., and Machado da Silva, G. (2011). CLN2. The Neuronal Ceroid Lipofuscinoses (Batten Disease), Oxford University Press.","DOI":"10.1093\/med\/9780199590018.001.0001"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/jpc.14890","article-title":"Neuronal ceroid lipofuscinosis type 2: An Australian case series","volume":"56","author":"Johnson","year":"2020","journal-title":"J. Paediatr. Child Health"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1177\/0883073820977997","article-title":"Cerliponase Alfa for the Treatment of Atypical Phenotypes of CLN2 Disease: A Retrospective Case Series","volume":"36","author":"Wibbeler","year":"2021","journal-title":"Child Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/febs.13593","article-title":"Plasma biomarkers for neuronal ceroid lipofuscinosis","volume":"283","author":"Hersrud","year":"2016","journal-title":"FEBS J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.bbadis.2012.08.012","article-title":"The neuronal ceroid-lipofuscinoses: A historical introduction","volume":"1832","author":"Haltia","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.pediatrneurol.2017.01.034","article-title":"Management strategies for CLN2 disease","volume":"69","author":"Williams","year":"2017","journal-title":"Pediatr. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0167-4838(98)00012-0","article-title":"Purification and characterisation of a tripeptidyl aminopeptidase I from rat spleen","volume":"1384","author":"Vines","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1474-4422(18)30368-5","article-title":"Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis","volume":"18","author":"Mole","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.bbadis.2006.07.001","article-title":"Diagnosis of the neuronal ceroid lipofuscinoses: An update","volume":"1762","author":"Williams","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1212\/01.wnl.0000267885.47092.40","article-title":"Neurological deterioration in late infantile neuronal ceroid lipofuscinosis","volume":"69","author":"Worgall","year":"2007","journal-title":"Neurology"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Nickel, M., and Schulz, A. (2022). Natural History Studies in NCL and Their Expanding Role in Drug Development: Experiences From CLN2 Disease and Relevance for Clinical Trials. Front. Neurol., 13.","DOI":"10.3389\/fneur.2022.785841"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1111\/epi.13820","article-title":"Photosensitivity is an early marker of neuronal ceroid lipofuscinosis type 2 disease","volume":"58","author":"Specchio","year":"2017","journal-title":"Epilepsia"},{"key":"ref_14","first-page":"e68","article-title":"Value of genetic testing for pediatric epilepsy: Driving earlier diagnosis of ceroid lipofuscinosis type 2 Batten disease","volume":"63","author":"Truty","year":"2022","journal-title":"Epilepsia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.pediatrneurol.2013.08.008","article-title":"Clinical, electrophysiological, imaging, and ultrastructural description in 68 patients with neuronal ceroid lipofuscinoses and its subtypes","volume":"50","author":"Jadav","year":"2014","journal-title":"Pediatr. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cca.2019.02.010","article-title":"Validity of a rapid and simple fluorometric tripeptidyl peptidase 1 (TPP1) assay using dried blood specimens to diagnose CLN2 disease","volume":"492","author":"Lukacs","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejpn.2020.07.009","article-title":"MRI in CLN2 disease patients: Subtle features that support an early diagnosis","volume":"28","author":"Havali","year":"2020","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","article-title":"Study of intraventricular cerliponase alfa for CLN2 disease","volume":"378","author":"Schulz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1055\/s-0043-1770143","article-title":"Language Delay in Patients with CLN2 Disease: Could It Support Earlier Diagnosis?","volume":"54","author":"Nickel","year":"2023","journal-title":"Neuropediatrics"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1080\/14737175.2021.1885374","article-title":"Managing CLN2 disease: A treatable neurodegenerative condition among other treatable early childhood epilepsies","volume":"21","author":"Huidekoper","year":"2021","journal-title":"Expert Rev. Neurother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.pediatrneurol.2020.04.018","article-title":"Intracerebroventricular Cerliponase Alfa for Neuronal Ceroid Lipofuscinosis Type 2 Disease: Clinical Practice Considerations From US Clinics","volume":"110","author":"Lehwald","year":"2020","journal-title":"Pediatr. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1177\/0883073819895694","article-title":"Review of Cerliponase Alfa: Recombinant Human Enzyme Replacement Therapy for Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2","volume":"35","author":"Lewis","year":"2020","journal-title":"J. Child Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.oret.2020.01.011","article-title":"Symmetric Age Association of Retinal Degeneration in Patients with CLN2-Associated Batten Disease","volume":"4","author":"Kovacs","year":"2020","journal-title":"Ophthalmol. Retin."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1136\/bjo-2022-321260","article-title":"Ongoing retinal degeneration despite intraventricular enzyme replacement therapy with cerliponase alfa in late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2 disease)","volume":"107","author":"Dulz","year":"2023","journal-title":"Br. J. Ophthalmol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/14\/8\/783\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:22:10Z","timestamp":1760109730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/14\/8\/783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["jpm14080783"],"URL":"https:\/\/doi.org\/10.3390\/jpm14080783","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]}}}